Companies Ro (Ro.co)

Ro (Ro.co)

New York

Total Offices: 2

824 Total Employees

Year Founded: 2017

View Website

We're Hiring!

Engineering 14 HR & Recruiting 3 Data & Analytics 1 AI & Machine Learning 1 Marketing 1 Operations & Support 1 Program & Project Management 1 Supply Chain & Procurement 1

View all jobs

Ro (Ro.co) Company Growth, Stability & Outlook in New York

Updated on September 16, 2026

What's the stability & growth outlook for Ro (Ro.co)?

The New York office is characterized by partnership-led, research-backed growth centered on GLP‑1 obesity care and an integrated care stack. Together, these dynamics suggest the New York location offers exposure to scaled collaborations and sustained commercial momentum aligned with the company’s current growth engine.

Key Insight for Candidates

At Ro’s New York HQ, teams execute pharma‑integrated GLP‑1 programs and publish real‑world outcomes, leveraging an end‑to‑end telehealth, labs, and pharmacy stack. This gives candidates proximity to partnerships, evidence, and product decisions driving nationwide obesity‑care access.

Evidence in Action

Pharma-integrated GLP-1 Access — Eli Lilly Zepbound vials (December 11, 2024) and Novo Nordisk Wegovy pill (early 2026) integrations anchor Ro’s GLP‑1 access. This gives New York teams a dependable growth lane to plan roadmaps, staffing, and patient operations around.
Outcomes-Led Growth Cadence — Real‑world outcomes for semaglutide and tirzepatide patients and ongoing obesity‑related research are publicized. This lets New York employees align work to measurable results, strengthening payer/employer dialogues and reinforcing durable program focus.

Positive Themes About Ro (Ro.co)

Strategic Partnerships: From its New York headquarters, the company activated direct manufacturer channels with Eli Lilly (Zepbound) and Novo Nordisk (Wegovy pill) via its telehealth platform, expanding access to on‑label GLP‑1s. These integrations indicate coordinated partnership execution that shapes growth for the New York team.
Strong Revenue Growth: With headquarters in New York, the business experienced a clear revenue reacceleration in 2024, largely powered by its GLP‑1 obesity‑care program. This momentum reflects a renewed top‑line trajectory that the New York organization is central to steering.
Innovation-Driven Growth: The New York office underpins a vertically integrated model (telehealth, labs/diagnostics, pharmacy) and ongoing obesity‑care outcomes research, enabling product and access innovation. This evidence‑driven posture supports broader commercialization conversations from a New York base.